| NCT06383390The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Retatrutide Cardiovascular disease, Chronic kidney disease, Obesity / overweight | BMI ≥27 · Established ASCVD/CKD | Ph 3 | Active, not recruiting | 745 | Feb 2029 | 1 | |
| NCT07165028A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Retatrutide, Tirzepatide MASH / NAFLD / liver fibrosis, Obesity / overweight | — | Ph 3 | Recruiting | 562 | Aug 2030 | — | |
| TRIUMPH-3A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease | Retatrutide Cardiovascular disease, Obesity / overweight | BMI ≥35 · Established CVD | Ph 3 | Active, not recruiting | 169 | Apr 2026 | — | |
| TRIUMPH-1A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight | Retatrutide Obesity / overweight, Osteoarthritis, Sleep apnea | BMI ≥30 | Ph 3 | Active, not recruiting | 134 | Apr 2026 | — | |
| TRIUMPH-2A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight | Retatrutide Obesity / overweight, Sleep apnea, Type 2 diabetes | BMI ≥27 | Ph 3 | Active, not recruiting | 98 | May 2026 | — | |
| NCT06260722Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | Retatrutide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 3 | Active, not recruiting | 77 | Aug 2026 | — | |
| NCT06297603Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) | Retatrutide Renal impairment, Type 2 diabetes | BMI ≥23 | Ph 3 | Active, not recruiting | 76 | Oct 2026 | — | |
| TRIUMPH-5A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Retatrutide, Tirzepatide Obesity / overweight | — | Ph 3 | Active, not recruiting | 65 | Dec 2026 | — | |
| TRIUMPH-6A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity | Retatrutide Obesity / overweight | — | Ph 3 | Active, not recruiting | 53 | Apr 2028 | — | |
| TRIUMPH-4A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee | Retatrutide Obesity / overweight, Osteoarthritis | BMI ≥27 | Ph 3 | Completed | 49 | Nov 2025 | — | |
| NCT06354660Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) | Retatrutide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 48 | Jan 2026 | — | |
| NCT04867785A Study of LY3437943 in Participants With Type 2 Diabetes | Dulaglutide, Retatrutide Type 2 diabetes | HbA1c 7-10.5% | Ph 2 | Completed | 43 | Jul 2022 | 2 | results |
| NCT05936151A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Retatrutide Chronic kidney disease, Obesity / overweight | BMI ≥27 | Ph 2 | Completed | 42 | Oct 2025 | 1 | |
| TRIUMPH-7A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | Retatrutide Obesity / overweight, Pain | BMI ≥27 | Ph 3 | Recruiting | 40 | Sep 2027 | — | |
| TRIUMPH-9A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight | Retatrutide Obesity / overweight | — | Ph 3 | Recruiting | 35 | Oct 2028 | — | |
| TRIUMPH-8A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Retatrutide Obesity / overweight | — | Ph 3 | Active, not recruiting | 31 | Jul 2027 | — | |
| NCT04881760A Study of LY3437943 in Participants Who Have Obesity or Are Overweight | Retatrutide Obesity / overweight | BMI 30-50 | Ph 2 | Completed | 28 | May 2022 | 2 | results |
| NCT05916560A Study of LY3437943 in Participants With Impaired and Normal Liver Function | Retatrutide Healthy volunteers, Hepatic impairment | BMI 19-42 | Ph 1 | Completed | 5 | Mar 2025 | — | |
| NCT04143802A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM) | Dulaglutide, Retatrutide Type 2 diabetes | BMI 23-50 | Ph 1 | Completed | 4 | Dec 2020 | 1 | |
| NCT05611957A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function | Retatrutide Healthy volunteers, Renal impairment | BMI 19-40 | Ph 1 | Completed | 4 | Sep 2023 | — | |
| NCT04823208A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM) | Retatrutide Type 2 diabetes | BMI 23-35 | Ph 1 | Completed | 4 | Jun 2022 | — | |
| NCT06313528A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943 | Retatrutide Obesity / overweight | BMI ≥30 | Ph 1 | Completed | 3 | Aug 2025 | — | |
| NCT06003465A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices | Retatrutide Healthy volunteers | BMI 18.5-32 | Ph 1 | Completed | 3 | Feb 2024 | — | |
| NCT05445232A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants | Retatrutide Obesity / overweight | BMI 27-40 | Ph 1 | Completed | 2 | Feb 2023 | — | |
| NCT05548231A Study of LY3437943 in Chinese Participants With Obesity Or Overweight | Retatrutide Obesity / overweight, Type 2 diabetes | BMI 27-40 | Ph 1 | Completed | 2 | Jul 2023 | — | |
| NCT06039826A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese | Retatrutide Obesity / overweight | BMI 27-40 | Ph 1 | Completed | 2 | Jul 2024 | — | |
| NCT03841630A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants | Retatrutide Healthy volunteers | BMI 19-40 | Ph 1 | Completed | 1 | Jul 2019 | — | |
| NCT06808802To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants | Retatrutide Healthy volunteers | BMI 22-35 | Ph 1 | Completed | 1 | Apr 2025 | — | |
| NCT05757531A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants | Retatrutide Healthy volunteers | BMI 18.5-32 | Ph 1 | Completed | 1 | Jun 2023 | — | |
| GZBFEffect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight | Retatrutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI 30-50 | Ph 2 | Recruiting | 1 | Mar 2027 | — | |
| NCT06982846A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia | Retatrutide Type 2 diabetes | BMI 25-45 | Ph 1 | Active, not recruiting | 1 | May 2026 | — | |
| NCT06982859A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus | Retatrutide, Semaglutide Obesity / overweight, Type 2 diabetes | — | Ph 1 | Recruiting | 1 | Nov 2026 | — | |
| NCT05959096A Study of LY3437943 in Healthy Participants With a High Body Mass Index | Retatrutide Healthy volunteers, Obesity / overweight | BMI 27-45 | Ph 1 | Completed | 1 | Jul 2024 | — | |
| NCT07629401Provide Pre-approval Expanded Access of LY3437943 | Retatrutide | — | — | Unknown | 0 | — | — | |
